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coma Council determined aspects to consider before
prescribing systemic therapy. Topics were assigned to expert reviewers who performed a topic-specific
literature review, referred to guidelines when available, and provided interpretation and expert opinion.Results: We recommend a systematic and holistic approach to assess patients with severe signs and
symptoms of AD and impact on quality of life before systemic therapy. Steps taken before commencing
systemic therapy include considering alternate or concomitant diagnoses, avoiding trigger factors,
optimizing topical therapy, ensuring adequate patient/caregiver education, treating coexistent infection,
assessing the impact on quality of life, and considering phototherapy.Limitations: Our work is a consensus statement, not a systematic review.Conclusion: The decision to start systemic medication should include assessment of severity and quality of
life while considering the individual’s general health status, psychologic needs, and personal attitudes
toward systemic therapies. ( J Am Acad Dermatol 2017;77:623-33.)
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section subheadings of this consensus statement)
mild-to-moderate disease that responds adequately
to optimized emollient use, avoidance of irritants
and disease triggers, and standard topical anti-
inflammatory therapies. However, many patients
with AD may not have adequate disease control
with these regimens of care or with phototherapy.CAPSULE SUMMARY
d Physicians should optimize topical
therapy before considering systemic
medications for atopic dermatitis.
d Patients who fail to respond should be
evaluated for exacerbating factors such
as cutaneous infection and for
alternative diagnoses such as allergic
contact dermatitis.
d The decision to start systemic therapy
depends on disease severity, impact on
quality of life, and risks and benefits of
systemic therapies for the individual
patient.For pediatric and adult pa-
tients with moderate-to-
severe AD that does not
respond to topical therapy
and for which phototherapy
is not a viable option, sys-
temic therapy is needed to
control skin inflammation,
reduce symptoms, prevent
flares, and improve quality
of life (QoL). The decision
to initiate a systemic medica-
tion for AD can be difficult,
given the known risks of
traditional immunosuppres-
sants. In a study from
Germany, 10% of patients
with AD received systemic
therapy with oral corticoste-
roids,2 although the proportion of children with AD
requiring systemic therapy is likely lower.3,4
Recent guidelines and systematic reviews from
national societies provide evidence-based sum-
maries of the safety and efficacy of systemic agents
used for AD treatment,5-9 and others discuss how
systemic treatments can be used effectively.10
Nevertheless, the question of when a patient is a
candidate for systemic therapy has received little
attention.11
Clinicians, patients, and caregivers consider many
factors when deciding whether a systemic agent
should be used. Most reviews state that failure to
respond to adequate topical therapy, need for
prolonged use of high-potency topical steroids, or
repeated flares makes a patient eligible, but there are
no universally accepted definitions of recalcitrance.
Given the lack of clarity in decision making and in an
effort to prevent overtreatment or undertreatment, a
group of experts on AD management, all councilors
or associates of the International Eczema Council
(IEC), conferred to provide consensus guidance for
clinicians in recognizing when a child or adult is
considered a candidate for systemic therapy.
METHODS
Authors participated in a face-to-face meeting to
delineate broad topic areas for consideration before
prescribing systemic therapy. Topic areas (thewere assigned to expert reviewers from 9 countries,
each of whom performed a literature review,
referred to guidelines when available, and
provided interpretation and expert opinion on that
topic area.RESULTS
This expert review group
recommends a systematic
approach to assess patients
with severe signs and/or
symptoms of AD and/or
impact on quality of life
before systemic therapy. We
reviewed the strengths and
weaknesses of methods to
measure disease severity
and discussed issues to
address before determining
that nonsystemic treatment
had failed. Finally, we sum-
marized the key steps to
follow before choosing to
start a systemic agent
(Fig 1). Consensus acrossthese areas is detailed in the following sections.
Severity-based scoring systems alone cannot
determine the need for systemic therapy: a
holistic assessment is needed
One approach for identifying a candidate for
systemic therapy is to utilize a disease severity score.
More than 20 AD scoring systems quantify disease
severity.12,13 The 2 most extensively validated are the
Scoring of Atopic Dermatitis (SCORAD), which in-
corporates the intensity of disease signs and extent
along with the patient-reported sleep loss and itch,
and the Eczema Area and Severity Index.14 Scoring
systems are used primarily in clinical trials and are
too time-consuming for routine clinical practice.
Moreover, these tools assess only part of the complex
thinking that underlies treatment selection.
Assessment of the impact of AD on the patient,
however, needs to include consideration of both
severity and quality of life. Even if the extent of
disease is small (eg, just the face, hands, or genital
area), the impact on the individual patient may still
be severe, negatively affecting a patient’s emotional
state, social functioning, activities of daily living, or
any combination of these. Furthermore, extent of AD
is hard to quantify because lesions are diffuse and
less circumscribed than in psoriasis, for example.
Using a SCORAD higher than 25 to define moderate-
to-severe disease is favored by many European
Abbreviations used:
AD: atopic dermatitis
IEC: International Eczema Council
NB-UVB: narrowband ultraviolet B
QoL: quality of life
SCORAD: SCORing Atopic Dermatitis Score
TCI: topical calcineurin inhibitors
TCS: topical corticosteroid
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several drawbacks to the use of a single scoring
system in identifying candidates for systemic
treatment.
A single, static (1 point in time) measurement of
severity may overestimate or underestimate the true
AD severity experienced by the patient, given the
characteristic exacerbations and remissions of AD.17
Serial measurements can provide information about
baseline severity, flares, and therapeutic response. It
is important to gauge the severity and frequency of
disease flares by using a variety of methods, as
flares are a major determinant of quality of life and
disillusionment with current therapy.18 Self-
assessment scores such as the Patient-Oriented
Eczema Measure and Patient-Oriented SCORAD
enable patient-derived assessment of the course
of the disease between consultations.19-21
Documentation of severe, extensive disease and/or
QoL impairment at several time points with adequate
topical therapy enables a holistic rationale for mov-
ing to systemic therapy.
Assess disease impact on QoL
AD can severely affect social lives and emotional
well-being, as well as academic and occupational
endeavors.22 Validated QoL measures can be useful,
but their use in the clinic may not be practical. For
example, Heinl et al identified the best-validated
instrument for measuring QoL with pediatric AD to
be the Childhood Atopic Dermatitis Impact Scale,
which contains more than 30 items.23 In some
practice settings, shorter, yet validated QOL scales,
such as the Dermatology Life Quality Index or
Skindex-16, may be useful to help document the
impact of the disease, which may not be readily
apparent through routine questioning. Chernyshov
et al recently reviewed the pros and cons of the
various instruments available for QOL measurement
in AD.24 Alternatively, clinicians may assess and
document QoL by using simple, open-ended ques-
tions, such as How is your atopic dermatitis affecting
you? or How does your atopic dermatitis affect your
life at home or at school/work? The frequency and
intensity of symptoms, such as itch, pain, and sleepdisruption can be assessed by using formal tools
such as the Patient-Oriented Eczema Measure, visual
analogue scales, or numeric rating scales.25
Treatment burden includes the time spent on treat-
ment and the costs of medications, physician visits
related to AD flares, and medication monitoring. If
the impact on QoL from symptoms and/or treatment
burden is significant in the eyes of the patient despite
efforts to establish an appropriate and feasible plan
of topical care (further discussed later), systemic
therapy should be considered and may be more
acceptable to patients and providers alike.
Alternative or concomitant diagnoses should
be considered before advancing to systemic
therapy
The diagnosis of AD is usually made clinically.
However, a correct diagnosis can sometimes be
challenging, particularly if clinical features are atyp-
ical (Table I). Careful history taking, examination,
and (sometimes) accompanying biopsy, laboratory
assessments such as potassium hydroxide, scabies
microscopic examinations, or patch testing26 should
be undertaken.
Ensure that adequate education has been
delivered to improve adherence to topical
therapy
It is important to ascertain whether failure of
topical treatment is due to the severity of the disease
(lack of efficacy of topical therapy) or lack of
adherence to the treatment when making the deci-
sion to begin systemic therapy. Adherence to optimal
topical management is challenging and can be
exhausting for some patients and caregivers. Most
prevalent is the fear of patients, caregivers, and
health professionals about use of topical anti-
inflammatory medications.27 However, the smell
and stains from tar preparations, the ‘‘feel’’ of a
topical ointment (vs an oil or cream), and the
messiness of certain topicals under clothes are
patient concerns that can be discussed and accom-
modated to improve adherence. In addition to ste-
roid phobia,28 there is fear of topical calcineurin
inhibitors (TCIs) related to the black box warning
mandated by the US Food and Drug Administration
in 2005. Although the black box warning was
initiated because of the theoretical risk of malig-
nancy, no signal for cancer risk has emerged;
nevertheless, the black box remains and requires
US pharmacists to warn patients.
If failure of therapy is due to lack of adherence
and/or topical corticosteroid (TCS) phobia, the first-
line intervention of choice is patient education.29-32 If
adherence to topical therapy cannot be optimized
Fig 1. Algorithm to decide when systemic immunomodulatory therapy is warranted in patients
with atopic dermatitis.
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Simpson et al 627despite proper education, the decision to start sys-
temic therapy rests on the clinician’s understanding
of the reasons for continued nonadherence and
whether those reasons can justify the risk and
expense of systemic therapy for a particular patient.
The need for overly complex topical regimens that
are not feasible for a particular patient may justify
moving to systemic therapy.
There are no evidence-based recommendations
for environmental trigger avoidance measures inpatients with AD. However, several factors poten-
tially provoke flares, most commonly, irritants such
as detergents, sweat, saliva, aeroallergens, contact
allergens, and psychologic stress.33
Patients need a trial of intensive topical
therapy
We advocate comprehensive patient education
and a period of intensive topical therapy (if needed
in a daycare setting), followed by reassessment of the
Table I. Differential diagnoses to consider in pediatric and adult patients with severe atopic dermatitis
Condition Clinical features Diagnostic work-up
Children and adults
Contact dermatitis (irritant or
allergic)
Atypical or localized distribution Patch testing for allergic contact
Severe, suberythrodermic psoriasis Less pruritus and lack of eczematous
change such as oozing/crusting
Biopsy
Severe seborrheic dermatitis Lack of pruritus with greasy scale in
scalp and folds in infants
Clinical diagnosis
Scabies infestation Inguinal, axillary, and genital papules.
Palmoplantar vesicles and burrows
in infants.
Mineral oil scraping
Widespread tinea corporis Annular papulosquamous lesions
without eczematous change
Skin scraping for microscopy and
culture
Children
Zinc deficiency Erosive plaques on face and groin
with fussiness
Zinc levels and genetic testing
Netherton syndrome/other
ichthyoses
Erythroderma, hair abnormalities, and
failure to thrive
Genetic testing
Immune deficiencies (eg, severe
combined immunodeficiency,
agammaglobulinemia, Wiskott-
Aldrich syndrome, hyperIgE
syndrome)
Sinopulmonary infections and failure
to thrive
Genetic and immunologic testing, as
well as total IgE (hyperIgE
syndrome)
Adults
Cutaneous T-cell lymphoma Lack of classic eczematous skin
changes such as oozing and
crusting
Skin biopsy and T-cell rearrangement
studies
IgE, Immunoglobulin E.
J AM ACAD DERMATOL
OCTOBER 2017
628 Simpson et aldisease impact on severity and quality of life.15
Authors agreed that the general approach should
be an intensive clearance period with a TCS followed
by a safe and individualized regimen of intermittent
TCSs, TCIs, or emollients to prevent flares. The
strength of prescribed TCSs should be appropriate
for patient age and the body locations being treated.
Exact treatment protocols varied among the authors,
but there was general consensus that the use of more
potent TCSs (medium- to high-potency, class I to III
in the United States, and class III to IV in Europe)
once or twice daily for 1 to 4 weeks provides a useful
way to gain control of severe disease, followed by a
taper in application frequency. Patient age should be
taken into consideration, with use of the strongest
steroid classes restricted to adolescents and adults.
Wet-wrap therapy and use of therapy after soaking in
a bath (particularly in cases in children) may also be
useful adjunctivemeasures to the application of TCSs
or TCIs to quickly reduce disease severity but will
increase the potency of the treatment.34
Should a patient improve during this induction
period, it may be possible to maintain disease control
by utilizing a medium-strength TCS or TCI applied 2
to 3 times weekly to normal-appearing skin at a site
of frequent flares (proactive therapy).35-38 Thisapproach has been shown to significantly reduce
relapses, ultimately requiring less total TCS/TCI with
negligible side effects.39 Patients who flare
frequently, despite TCS induction followed by a
proactive approach, are candidates for systemic
therapy. Overuse of topical therapy (potency, fre-
quency, and duration) despite controlled disease
represents an indication for systemic therapy.
Finally, the need for repeated courses of oral or
intramuscular steroids, a management strategy
discouraged by AD treatment guidelines, would be
another indication for initiating more appropriate
systemic therapy.Infection should be sought and treated as
appropriate
Bacterial or viral infections should be identified
and treated before considering systemic therapy.
Many individuals affected by AD have skin and
nasal colonization with Staphylococcus aureus,40
increasing the risk of cutaneous infection.41
Furthermore, AD flares are accompanied by a shift
in the microbiome, with an increased percentage of S
aureus and reduced bacterial diversity.42 Certain
viral infections have also been associated with AD
Table II. Most common on-label and off-label systemic therapies in AD
Drug (in alphabetical
order)
Approved
for AD?
Estimated efficacy
(% reduction
in composite
severity scores) Dose range Common or serious side effects Monitoring required*
Azathioprine No 26%-39%5 Adult: 1-3 mg/kg/day;
Pediatric: 1-4 mg/kg/day
Hematologic abnormalities,
skin and other malignancies,
hepatosplenic lymphoma,
and CNS infections such as
PML
CBC, CMP, thiopurine
methyltransferase
Cyclosporine No in
United States,
yes in Europe
53%-95%5 Adult and pediatric:
2.5-5 mg/kg
Renal insufficiency,
hypertension, and drug
interactions
CBC, CMP, magnesium,
uric acid, lipids, and
blood pressure
Dupilumab Yes 73%62 Adult: 600 mg loading
followed by 300 mg/wk
Injection site reactions and
conjunctivitis
None
Methotrexate No 42%5 Adult: 7.5-25 mg weekly
Pediatrics: 0.2-0.7 mg/kg
weekly
Hepatoxicity, hematologic
abnormalities, teratogen,
gastrointestinal intolerance,
nausea, and fatigue
CBC, CMP
Mycophenolate No Unknown 1.0-1.5 g orally twice daily
Pediatric: 30-50 mg/kg daily
Gastrointestinal, teratogen CBC, CMP
AD, Atopic dermatitis; CBC, complete blood count with differential and platelets; CMP, complete metabolic panel with basic chemistries and liver function tests; CNS, central nervous system; PML,
progressive multifocal leukoencephalopathy.
*See published review by Sidbury et al7 for more complete and detailed information regarding dosing and drug monitoring.
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630 Simpson et alexacerbation (eczema herpeticum, eczema cox-
sackium, and molluscum).43
Systemic antibiotics are usually required for treat-
ment of cutaneous bacterial infection, especially
before initiation of systemic therapy,11 as persistent
infection may impair treatment responses.44 Systemic
antibiotics should be avoided in the absence of signs
of infection (ie, these should not be used as a systemic
treatment for AD and do not effectively reduce S
aureus colonization).45 Antiseptic baths, most
commonly with 0.005% sodium hypochlorite (dilute
bleach), reduce disease severity46 and could be
considered before systemic therapy, although this
approach is not universally adopted and may have a
greater ameliorative effect on the barrier and inflam-
mation thanon S aureus colonization. Topical or even
systemic antifungal treatment could be considered for
head and neck dermatitis, which is postulated to be
driven by secondary yeast colonization, although the
results of clinical trials have been conflicting.47
Possible allergic triggers should be considered
and managed as appropriate
Patients with AD have a higher rate of allergic
sensitization, including both type I reactions to
aeroallergens (eg, animal dander and grass pollens)
and type IV delayed allergic responses to contact
allergens. Fragrances, preservatives (particularly pro-
pylene glycol and methylchlorothiazolinone) and
emulsifiers in emollients and topical steroid creams
are a frequent source of contact allergens for patients
with AD.25,48-51 If the patient’s history and physical
examination results suggest allergic triggers that
exacerbate disease, further investigation to identify
these triggers is appropriate (eg, referral to allergy
services for skin prick testing or patch testing).
Phototherapy should be considered before the
use of other systemic therapy if accessible and
practical
Phototherapy is recommended as second-line or
adjuvant therapy in selected patients for moderate-
to-severe AD, especially in adults and older chil-
dren.7,52 Systematic reviews have identified the
greatest efficacy for narrowband ultraviolet B (NB-
UVB) (311-313 nm) and ultraviolet A-1 (340-
400 nm).53,54 Psoralen with ultraviolet A radiation is
associated with a greater risk of cutaneous malig-
nancy and should be considered only in adults for
whom NB-UVB has shown inadequate efficacy.55
Phototherapy is also efficacious in the pediatric
population,7,56 but the long-term risk of skin cancer,
especially in fair-skinned individuals, is not fully
understood, suggesting the need for caution in this
population, especially in patients who might receive
systemic immunosuppressivemedication later in life.Optimal benefit requires a prolonged course (;24
phototherapy treatments) to induce sustained remis-
sion, and adherence to phototherapy can be partic-
ularly challenging. Phototherapy is often poorly
tolerated in highly inflamed AD and may be better
tolerated after acute disease control with intensive
topical or wet-wrap therapy.
Typically, 2 or 3 treatments per week of NB-UVB
are used for 6 to 12 weeks57 or longer.7 If no
response is seen within 8 to 12 weeks, or if AD
recurrently flares during phototherapy, we recom-
mend discontinuation. If AD improves with photo-
therapy but relapses rapidly, the safety risks of
frequent retreatment or use of maintenance photo-
therapy must be weighed against those of systemic
therapy. For many patients, the inconvenience of
office-based phototherapy is untenable and home
phototherapy may be a useful option; 1 study of
patients with psoriasis showed results of home
phototherapy similar to those of in-office use.58
Phototherapy should be discontinued if cyclo-
sporine or other systemic treatments (eg, azathio-
prine or mycophenolate mofetil) are initiated to
avoid the synergistic risk of inducing skin malig-
nancy. Combining methotrexate with phototherapy
is thought to be associated with lower risk than other
immunosuppressants and has been used for psoria-
sis treatment.59
Factors to consider when choosing a systemic
agent
Each patient’s situation is unique, and several
factors influence the discussion between patient/
caregiver and physician that leads to therapeutic
decision making.60 These include existent comorbid-
ities and results of baseline investigations; patient age;
anticipation of pregnancy and family planning issues
for both male and female patients; and the patient’s
previous clinical experience, including with systemic
agents.61 Sharing information about treatment effi-
cacy and potential side effects with the patient and
family is also important. The most commonly used
systemic medications for AD are summarized in
Table II. A shared decision-making process should
then be undertaken, weighing these factors previ-
ously discussed herein with the risks and benefits of
the individual agents. The actual choice of any 1
systemic agent is beyond the scope of this article.
A future consideration: will the availability of
targeted immunomodulation with fewer safety
risks lower the threshold for utilization of
systemic agents?
Several emerging therapies are showing evidence
of efficacy and short-term safety that are potentially
J AM ACAD DERMATOL
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therapy.62 Prospective registries will be useful to
assess long-term safety and efficacy profiles, ideally
allowingcomparisonsbetweenconventional systemic
immunosuppressants andnovel emerging agents. The
Treatment of Atopic Eczema Registry Taskforce has
just reached consensus on a core data set for prospec-
tive registries for phototherapy and systemic therapies
to facilitate comparison and pooling of data, should
more than 1 registry be established.63
If proven both efficacious and safer than conven-
tional immunosuppressive therapies (both short-
and long-term therapy), systemic biologic and
small-molecule therapies could lower the bar toward
use for more moderate disease, not only to improve
disease response and quality of life, but also to
potentially prevent disease progression and future
comorbidities. The long-term safety and accessibility
of these newer interventions will enter into the
decision-making equation for patients in the future.CONCLUSION
This article provides a framework of thinking to
inform patients and physicians confronted with the
possibility of commencing systemic therapies for se-
vere AD in adult or pediatric practice. We purposely
offered no definitive Boolean yes/no guidelines, but
have instead offered guidance on the complex con-
siderations in making this decision (Fig 1). The deci-
sion to start a systemic agent should ideally include
assessments of severity and quality of life, while also
allowing consideration of individual factors. Some of
these additional individual factors are patient prefer-
ences, impact on personal life, prior topical therapy,
financial implications, and comorbidities. The ultimate
decision to commence systemic therapy will depend
on the joint exploration of these many factors by the
patient/caregiver and providers, taking into account
the patient’s psychologic needs, disease severity, and
personal attitudes to systemic therapies.
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